A
AskGene
Developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease
About AskGene
AskGene Pharma is a pioneering biotechnology company specializing in the development of cytokine prodrugs aimed at improving the safety and efficacy of cancer treatments. Founded in 2012, the company operates at the intersection of science, technology, and medicine, leveraging its proprietary SmartKine platform to extend the pharmacokinetics of cytokines while minimizing peripheral toxicity. This innovation allows AskGene to create next-generation prodrugs that address unmet medical needs, particularly in the field of oncology.
The company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, primarily focusing on advanced gastric and gastroesophageal junction cancers. AskGene's business model revolves around the research, development, and commercialization of its proprietary cytokine prodrugs. Revenue is generated through licensing agreements, partnerships, and direct sales of its therapeutic products.
AskGene's commitment to innovation is evidenced by its world-class team of scientists and its active participation in clinical trials and medical conferences. The company recently dosed its first patient in a Phase 3 pivotal trial for ASKB589, a promising treatment for advanced gastric cancers, and presented interim results at the ASCO GI 2024 conference.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Camarillo, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 41.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Oct 2024 | $35M | $141M | TF Capital · Jiangsu Aosaikang Pharmaceutical | ↗ |
| SERIES AOther financing | Jul 2023 | $0 | — | Qiming Venture Partners | — |
Growth signals
Latest recorded traffic for AskGene is 1.2K monthly website visits, down 36.8% over the last three months. AskGene's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
TF Capital
Qiming Venture Partners
Jiangsu Aosaikang Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AskGene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AskGene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.